Published On : August 2026
The landscape across the medical devices outsourcing and sterile manufacturing market spans pharmaceutical CDMOs and sterile fill specialists, drug delivery and packaging systems companies, and device manufacturing and engineering specialists.
These three groups enter from genuinely different directions, and their capabilities reflect where they came from rather than a common starting point.
Pharmaceutical CDMOs bring sterile fill capability and pharmaceutical quality systems built for medicinal products.
Drug delivery and packaging companies bring container, device and delivery system engineering alongside high-volume component production.
Device manufacturing specialists bring assembly, electronics and precision production capability developed for device products.
Combination products sit at the intersection of all three, which is why that category has drawn participants from every direction and why capability there is unevenly distributed.
Certification scope rather than general standing determines what a provider can actually take on, and it varies considerably even between similarly sized firms.
Sterile and aseptic capacity is the scarcest capability in the market, and providers holding it hold genuine commercial leverage.
Consolidation has been active, with acquisitions building service breadth because customers value single-partner coverage.
This page organises providers by type and describes general positioning rather than ranking them or claiming quality outcomes.
Site-level rather than corporate-level assessment is the practical approach in this market, since a large provider's capability varies considerably between facilities. A certification held by the group does not establish that the site proposed for a given product holds it.
Private equity ownership is common across parts of this landscape, and ownership change can bring investment or rationalisation depending on the acquirer's plan.
Service breadth has become the dominant consolidation logic in this market, since customers increasingly prefer fewer partners covering more of the chain. Acquisitions have accordingly targeted capability gaps rather than scale alone, and the resulting groups are assembled portfolios whose integration quality varies considerably between them.
Sidefarma, Recipharm, Vetter Pharma, Fareva, Delpharm and Catalent anchor this tier as contract development and manufacturing organisations with pharmaceutical origins.
Their defining capability is sterile fill, which is the scarcest and most capital-intensive capacity in this market.
Pharmaceutical quality systems are their foundation, built for medicinal products and extended into device and combination work.
That origin is an advantage in combination products, where the pharmaceutical framework frequently leads, and a gap where pure device assembly is required.
Vetter Pharma holds a substantial position in aseptic filling of injectable and drug delivery products specifically.
Catalent operates across a broad development and manufacturing range extending well beyond devices into wider pharmaceutical services.
Sidefarma operates from Portugal within the Iberian cluster this report identifies, combining pharmaceutical manufacturing with device-adjacent capability.
Recipharm, Fareva and Delpharm hold substantial European footprints across multiple sites and service lines.
The sterile capabilities this tier operates are covered among the sterile capabilities these providers operate.
For customers with sterile or combination product requirements, this tier is generally the natural starting point.
Capacity commitments in this tier are frequently made years ahead, and available near-term slots are scarce for aseptic work in particular. Customers planning launches work backward from capacity availability rather than assuming it can be secured when needed.
Their pharmaceutical origins bring documentation and validation conventions that device-origin customers sometimes find heavier than expected. Neither approach is wrong, but the mismatch surfaces during technical transfer and is worth anticipating rather than discovering mid-project.
Several providers in this tier operate across more than one regulated contract manufacturing category, and the containment-focused end of pharmaceutical CDMO work is covered separately in our analysis of the high potent APIs market, which shares this market's customer population and its emphasis on certification scope and qualified capacity.
Gerresheimer, SCHOTT Pharma, Nemera, Stevanato Group, West Pharmaceutical Services, Bespak, TekniPlex Healthcare and Sanner Group anchor this tier.
These companies build containers, delivery devices and packaging systems, frequently at very high volume.
Their capability sits in materials science, precision moulding, glass and polymer processing and delivery device engineering.
Several have extended from component supply into contract manufacture of complete delivery systems, which moves them up the value chain toward their own customers.
That extension has been a defining strategic move across this tier over recent years and has intensified competition with the CDMO group.
Gerresheimer and SCHOTT Pharma hold established positions in pharmaceutical primary packaging including glass systems.
Nemera and Bespak focus on drug delivery devices specifically, spanning inhalation, injection and other administration routes.
Stevanato Group and West Pharmaceutical Services combine containment components with device and assembly capability.
TekniPlex Healthcare and Sanner Group bring materials and packaging systems capability including barrier and protective solutions.
For customers whose requirement centres on delivery systems or primary packaging, this tier holds capability the other groups generally lack.
Their component businesses give them volume economics that pure contract manufacturers lack, since the same production feeds both component sales and assembled system supply. That dual channel is a structural advantage in delivery system work and part of why this tier has moved up the value chain successfully.
Phillips-Medisize, Nolato Medical, Integer Holdings, Viant Medical, Sanmina and Flex Health Solutions anchor this tier.
Their origins are in device and precision manufacturing rather than pharmaceutical production, and their strengths follow accordingly.
Precision moulding, assembly, electronics integration and engineering development are their core capabilities.
Sanmina and Flex Health Solutions come from electronics manufacturing services backgrounds, which is directly relevant as devices incorporate more electronics and connectivity.
That electronics capability is increasingly differentiating as connected devices grow, and it is a genuine gap in the other two tiers.
Integer Holdings and Viant Medical hold substantial positions in device manufacturing including work for higher-classification products.
Nolato Medical operates across polymer components and complete device manufacture with a substantial European footprint.
Phillips-Medisize combines device design and manufacture across drug delivery and diagnostic products.
Sterile capability varies considerably across this tier and should be verified against the specific requirement rather than assumed from general standing.
For customers with electronics-containing or precision-engineered devices, this tier is generally the closest capability match.
Design and engineering capability in this tier extends to development partnership rather than execution alone, which suits customers wanting a partner to solve problems rather than follow a specification. That capability is less common in the packaging and CDMO tiers and is a genuine differentiator where it exists.
Contract electronics backgrounds bring supply chain capability across component sourcing that device-only manufacturers may lack, which matters increasingly as devices incorporate more electronic content. That sourcing depth is a genuine advantage where component availability is a programme risk.
A customer with sterile fill requirements is generally best served by pharmaceutical CDMOs, where that capability is core.
A customer whose product centres on a delivery system or primary packaging will find the delivery and packaging tier holds the relevant engineering.
A customer with electronics-containing or precision-engineered devices should look to device manufacturing specialists.
A customer with a combination product needs capability across frameworks, and providers from any tier may hold it depending on what gap each has closed.
Certification scope should be verified against the specific product and market plan rather than accepted as general assurance.
Sterile and aseptic capacity availability should be established early, since qualified capacity is genuinely constrained and lead times can be extended.
Sterilization method coverage warrants direct enquiry, particularly given the uncertainty surrounding ethylene oxide.
Minimum volume requirements determine whether a provider is realistically available to smaller programmes.
Provider fit depends substantially on customer profile, as covered among the customer types these providers serve.
A structured evaluation generally works best by confirming certification scope and capacity availability first, then capability match, and only then commercial terms.
Site visits and technical discussions with the operations team, rather than commercial presentations, consistently reveal more about whether a provider can actually deliver. Customers who invest that time before committing generally encounter fewer difficulties during transfer.
Reference conversations with comparable customers are worth pursuing, particularly regarding how a provider handled a problem rather than how it performs when everything runs smoothly.
A contract development and manufacturing organisation provides both development and manufacturing services. In this market CDMOs with pharmaceutical origins are distinguished by sterile fill capability, the scarcest capacity available.
A drug delivery device company designs and manufactures the systems that administer medicines, spanning inhalation, injection and other routes. Several have extended from component supply into contract manufacture of complete systems.
Contract electronics manufacturers bring electronics integration and precision assembly capability from outside healthcare. This is increasingly relevant as devices incorporate more electronics and connectivity.
Certification scope should be verified against the specific product and market plan, sterile capacity availability established early given genuine constraint, and sterilization method coverage confirmed directly. Capability match matters more than provider scale.